Gilead Sciences, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:GILD) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends Documents

Quarterly Annual

Total assets 56.43 B55.72 B58.53 B59.02 B56.28 B49.36 B Total liabilities 37.35 B36.13 B37.08 B36.91 B32.85 B37.62 B Total equity 19.08 B19.59 B21.46 B22.62 B23.43 B11.74 B Total liabilities & shareholders' equities 56.43 B55.72 B58.53 B59.02 B56.28 B49.36 B Total debt 24.95 B24.95 B24.94 B24.94 B22.17 B26.25 B Net debt 24.95 B24.95 B24.92 B22.89 B22.16 B26.25 B

News

Top Research Reports for Toyota Motor, CrowdStrike & Welltower

Can Bixlenvo Unlock New Growth for Gilead's HIV Business?

Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?

Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?

Stock Market Today: Nasdaq Sinks As Crude Prices Climb; These Oil Names Break Out (Live Coverage)

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know

FDA Approves Gilead's New Single Tablet HIV Regimen - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo - TipRanks.com

Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection

GSK Stock: Still One Of My Top Healthcare Picks (NYSE:GSK)

EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC

Making Drugs With AI: Biopharma Giants Gear Up For New Arena